Wednesday, November 25, 2009, 9:13am EST - Canadian Markets open in 17 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Dendreon Corp. (DNDN)

 On Nov 24: 27.20 USD   0.00 (0.00%)  
MORE ON DNDN
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Dendreon Corporation (NGM:DNDN) Delayed quote dataEdit
Pre-Market: 27.45 Up 0.25 (0.92%) as of 8:38am EST on 11/25/09
Last Trade: 27.20 USD
Trade Time: Nov 24
Change: 0.00 (0.00%)
Prev Close: 27.20
Open: N/A
Bid: 27.30 x 1000
Ask: 27.43 x 300
1y Target Est: 3.34
Day's Range: N/A - N/A
52wk Range: 2.55 - 30.42
Volume: 1,500
Avg Vol (3m): 3,030,950
Market Cap: 3.15B
P/E (ttm): N/A
EPS (ttm): -1.16
Div & Yield: N/A (N/A%)
Dendreon Corp. (DNDN)
1d  5d  3m  6m  1y  2y  5y  max 
 Add DNDN to Portfolio   Download Data

HEADLINES
• Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
PRNewswire (Wed 7:30am)
• Cel-Sci's History of Disappearing Drugs: BioBuzz
at TheStreet.com (Tue 9:20am)
• BioCryst Bull Blames Conspiracy for Stock's Fall: BioBuzz
at TheStreet.com (Tue 6:45am)
• Dendreon says FDA will disclose Provenge’s fate by May 1
at bizjournals.com (Fri, Nov 20)
• May Day For Dendreon
at CNBC (Fri, Nov 20)
• Dendreon's Provenge gets FDA review date
AP (Fri, Nov 20)
• Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Wall Street Transcript (Fri, Nov 20)
• UPDATE - FDA says Dendreon's drug application is complete
at Reuters (Fri, Nov 20)
• Dendreon Receives FDA Acknowledgement of Complete Response
PRNewswire (Fri, Nov 20)
• Biotech Stock Mailbag: FDA Playbook
at TheStreet.com (Fri, Nov 20)
• This Is Why You're Not Making Money in the Market
at Motley Fool (Tue, Nov 17)
More Headlines for DNDN...
ANALYST
EPS Est (next year) (Dec-07) : N/A
EPS Est (in 2 years) (Dec-08) : N/A
Avg Rec (current)*: 3.7
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics that harness the immune system to fight cancer.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices